For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Multiplex imaging of tumor tissue samples allows for improved biomarker discovery and increased accuracy in predicting patient therapeutic responses
Published 13th October, 2021
Following the success of monotherapy checkpoint inhibitors for cancer treatment, researchers are looking at combinations of established and new immunotherapies to extend the success of these treatments to increased patient numbers. However, leveraging the host immune system to fight cancer requires a more complete understanding of how components within the tumor microenvironment interact to promote or block tumor progression.
Previous methods used to analyze the tumor microenvironment, such as immunohistochemistry, can limit the number of biomarkers studied per sample. To overcome this limitation, many have transitioned to multiplex imaging. This application combines the study of multiple biomarkers in a tissue section with the capability to profile the spatial organization of each biomarker, either alone or in combination, to determine the tissue motifs of each tumor.
In this application note, we highlight work from Abcam's in-house research laboratories and Drs Koei Chin and Joe Gray from the Department of Biomedical Engineering at the Oregon Health and Science University (OHSU), which demonstrates the successful implementation of Abcam antibodies to key immuno-oncology targets in different multiplex imaging solutions.